Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers
These findings highlight the systemic manifestations of variant transthyretin amyloidosis associated with the TTR V142I variant and underscore the need for increased awareness and earlier diagnostic efforts in high-risk populations.
Authors
- Jacob Joseph (ORCID: https://orcid.org/0000-0001-8291-2027)
- Leland E. Hull (ORCID: https://orcid.org/0000-0002-5736-6543)
- Jeffrey P. Ferraro (ORCID: https://orcid.org/0000-0002-4111-2055)
- Lina Brinker (ORCID: https://orcid.org/0000-0002-8888-1695)
- Fatai Y. Agiri (ORCID: https://orcid.org/0009-0004-6701-3559)
- Steven Roblin
- Tyler J. Nelson (ORCID: https://orcid.org/0000-0001-5216-7337)
- Anthony Gao (ORCID: https://orcid.org/0000-0001-6781-7873)
- Josef Stehlik
- Kathryn M. Pridgen
- Kyong-Mi Chang
- Craig C. Teerlink
- Spencer Carter
- Christos P. Kyriakopoulos
- Konstantinos Sideris
- Dan Berlowitz
- Catherine Tcheandjieu
Institutions
- Gladstone Institutes (US)
- University of Massachusetts Lowell (US)
- Alnylam Pharmaceuticals (United States) (US)
- University of Utah (US)
- Providence VA Medical Center (US)
- Massachusetts General Hospital (US)
- VA Salt Lake City Healthcare System (US)
- Philadelphia VA Medical Center (US)
- Providence Center (US)
- George E. Wahlen Department of VA Medical Center (US)
Publication Details
- Journal
- JACC CardioOncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jaccao.2025.12.006
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00